Jan 2 (Reuters) - Sciele Pharma Inc SCRX.O said the U.S. Food and Drug Administration approved all four dosage strengths of its Sular formulation to treat high blood pressure.
The new formulation, which uses Britain's SkyePharma Plc's SKP.L Geomatrix technology, provides a lower dose of Sular for each of its current doses, Sciele Pharma said in a statement.
Sciele expects to launch the new formulation in the first quarter. (Reporting by John Tilak in Bangalore; Editing by Vinu Pilakkott)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.